Role of thyroid hormone therapy in depressive disorders.
Level 5 - mechanism / opinion, no new human data
Narrative literature review without systematic review or meta-analysis methodology.
PubMed 34129186 · doi:10.1007/s40618-021-01600-w
What was done
The authors conducted a literature search to review evidence on the use of thyroid hormones, specifically triiodothyronine (LT3) and levothyroxine (LT4), as add-on treatments alongside psychotropic medications in patients with unipolar and bipolar depressive disorders.
What was found
No numerical values, effect estimates, or sample sizes were reported in the abstract. The authors report that LT3 appears to accelerate and augment antidepressant response in refractory depression, while supraphysiologic doses of LT4 show efficacy in open-label and placebo-controlled studies for rapid-cycling and prophylaxis-resistant bipolar disorder, as well as acute refractory depression. Functional PET imaging studies noted that supraphysiologic LT4 modulated cerebral activity in the anterior limbic network.
Why it matters
It outlines adjunctive thyroid hormone therapy as a potential pharmacological option for patients with treatment-resistant unipolar and bipolar depression.
Limits
As a narrative review, the synthesis lacks systematic search criteria, quality appraisal of included studies, and quantitative data. The abstract provides no specific patient counts, effect sizes, statistical measures, or data regarding the safety and adverse effects of supraphysiologic thyroid hormone administration.
Cited by
- context Functional psychiatry uses T3 to treat conditions like manic depression and schizophrenia due to T3 receptor sites in the brain.